METRIOPHARM - Key Persons

Job Titles:

• Managing Director
• Member of the Board
• Senior Advisor

Christoph von Moos is Managing Director Senior Advisor at Bank Vontobel AG. He has held management and executive positions at various banks. He advises clients on all financial matters and also assists them with private equity investments. Christoph von Moos was elected to the Board of Directors of MetrioPharm AG for a further three years at the 17th Annual General Meeting on June 20th, 2023.

Job Titles:

• Member of the Board

Dr. Jörk Zwicker has a technical background in chemistry and biology and is a senior partner at Zwicker Schnappauf & Partner (ZSP) Patentanwälte PartG mbB. For more than 25 years, he has been advising both start-up companies and large corporations on the strategic development, defense and enforcement of their intellectual property rights, in particular patents for biological agents such as Praluent®, Dupixent®, Toujeo®, Altuvoct®, Gohibic® and Enjaymo®. In the strategic development of product-relevant intellectual property portfolios, Dr. Zwicker's focus is on life cycle management and the interaction between patent and regulatory law. Dr. Zwicker is also Chief Legal Officer of Eisbach Bio GmbH. Dr. Jörk Zwicker was elected to the MetrioPharm AG Board of Directors for a three-year term at the Extraordinary General Meeting held on April 17, 2025.

Job Titles:

• Member of the Board
• Global Healthcare Leader

Dr. Martina Muttke is an accomplished global healthcare leader with over 25 years of experience in the biopharmaceutical industry. She held senior leadership positions in major global companies, including Senior Vice President at Galderma, where she built and led the global Medical Affairs function. Prior to that, she was Group Vice President at Shire/Takeda, where she was responsible for medical activities in more than 50 countries and oversaw over 200 product launches. Her extensive international experience spans Europe, Latin America and global markets, with leadership roles at Bayer and other leading healthcare companies. Dr. Muttke is now a partner at Coulter Partners, where she advises and guides boards and C-suite executives on building high-performance leadership teams and shaping organizational strategies. She holds a doctorate in medicine from the University of Cologne and completed the Advanced Management Program at Harvard Business School. She is also an ICF-certified executive coach and investor & advisor to biotech and healthcare startups. Dr. Muttke was elected to the MetrioPharm AG Board of Directors for a three-year term at the Extraordinary General Meeting held on April 17, 2025.

Job Titles:

• Managing Director

Job Titles:

• Chairman of the Board
• President of the Board
• Chairman of the Venture Capital and Corporate Finance

Jörg Gruber is Chairman of the venture capital and corporate finance boutique Clubb Capital Limited in London and has been assisting emerging biotechnology companies since the early 1990s. His past clients include BioMarin, YM BioSciences and Raptor Pharmaceuticals. Prior to his career in venture capital, he was a banker and investment banker with UBS, Goldman Sachs and Lehman Brothers. He is Chairman of Constant Therapeutics LLC and advisor to Eisbach Bio GmbH. Previously, he served on the board of FORBIUS (Formation Biologics Inc.) until the latter's acquisition by Bristol Myers in the fall of 2020. He has been advising MetrioPharm since 2009, is confirmed as a member of the Board of Directors of MetrioPharm AG since 2018 and was elected as Chairman on 4 September, 2025.

Job Titles:

• Member of the Scientific Advisory Board
• Head of Neuromuscular Research, Head

Dirk Fischer, MD, PhD, Head of Neuromuscular Research, Head Physician of Neuro- and Developmental Pediatrics and Head of Electrophysiology at University Children's Hospital Basel (since 2008), Head Physician of Department of Internal Medicine at Kantonsspital Bruderholz (since 2011), and Head Physician at Department of Neurology of University Hospital Basel (since 2007). His international studies included stays in Madrid, Dublin, Buenos Aires, and London, as well as a postdoctoral fellowship at the Centre National de la Recherche Scientifique (CNRS) in Paris (2003-2005) focusing on hereditary muscular and peripheral neurological diseases such as Duchenne muscular dystrophy.

Job Titles:

• Member of the Scientific Advisory Board
• Full Professor of General Pathology and Immunology, University of Catania

Ferdinando Nicoletti, MD, PhD, Full Professor of General Pathology and Immunology (since 2011) at the University of Catania (Italy). Graduated at the University of Catania in 1987 in Medicine and Surgery and specialized in Allergology and Clinical Immunology at the University of Milan (Italy) in 1990. Ferdinando Nicoletti has been external consultant at the Institute for Inflammation Research, Righsospitalet University Hospital, Copenhagen, Denmark, from 1999 until 2010; Visiting Professor at the School of Medicine of the University of Belgrade, Serbia, in 2004; Honorary Professor at Tblisi State Medical University (Georgia) in 2023.

Job Titles:

• Member of the Scientific Advisory Board
• Professor of Paediatric Neuromuscular Disease, University of Oxford / Laurent

Servais, MD, PhD, Professor of Paediatric Neuromuscular Disease at the University of Oxford and invited professor at the University of Liège, specialized in spinal muscular atrophy, Duchenne Muscular Dystrophy, and Myotubular Myopathy. Educated in Medicine, Paediatrics, Child Neurology, and Myology in France and Belgium, he leads two newborn screening programs in UK (SMA) and Belgium (Genomic Newborn screening). His research focuses on innovative outcome measures using wearable devices and newborn screening. He sees patients in UK and in Belgium, and leads annual consultations in Egyptian and Romanian hospitals.

Job Titles:

• Member of the Scientific Advisory Board
• Emeritus, Institute for Research in Biomedicine Bellinzona

Marcus Thelen, PhD, is Honorary Professor at the University of Bern. In 2000, he co-founded the Institute for Research in Biomedicine (IRB) in Bellinzona and headed the Signal Transduction Laboratory until his retirement in 2022. In 1989, he joined the group of Alan Aderem in the Laboratory of Cellular Physiology and Immunology of the Cohn/Steinman Department at Rockefeller University, focusing on cytokine-mediated phagocyte priming and signal transduction. Following a Swiss National Science Foundation award, Marcus led a research group on leukocyte signal transduction in Bern. Marcus received his PhD from the University of Bern, specializing in inflammation and chemokines at the Theodor Kocher Institute.

Job Titles:

• Chief Executive Officer

Substantial collaborations and licensing agreements with major international pharma and biotech companies Multiple financing transactions including a reverse IPO at the Alternative Investment Market (AIM) of the London Stock Exchange 2019-2021 Development and sale of the German pharma start-up MYR GmbH to Gilead Sciences Inc. for 1.15 billion plus a milestone payment of a further 300 million Thomas Christély has more than 30 years of experience in general management, finance, corporate & business development at board level - thereof more than 25 years with private and listed biotech and pharmaceutical companies in Europe and the U.S. As CEO of MetrioPharm he focuses on corporate & business development and financing.